Wedbush Weighs in on Arcus Biosciences, Inc.’s FY2026 Earnings (NYSE:RCUS)

Arcus Biosciences, Inc. (NYSE:RCUSGet Rating) – Stock analysts at Wedbush raised their FY2026 earnings estimates for shares of Arcus Biosciences in a research note issued on Wednesday, May 11th. Wedbush analyst R. Driscoll now expects that the company will earn $14.22 per share for the year, up from their prior estimate of $13.96.

Arcus Biosciences (NYSE:RCUSGet Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($1.79). Arcus Biosciences had a return on equity of 8.25% and a net margin of 14.67%. During the same period in the prior year, the business earned ($1.08) earnings per share.

Other equities research analysts also recently issued research reports about the company. Truist Financial increased their price objective on Arcus Biosciences from $70.00 to $77.00 in a research report on Friday, February 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research report on Friday, April 1st. TheStreet upgraded Arcus Biosciences from a “d” rating to a “c” rating in a research report on Monday, March 21st. Finally, Zacks Investment Research downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 1st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $60.86.

Arcus Biosciences stock opened at $19.37 on Thursday. Arcus Biosciences has a one year low of $16.74 and a one year high of $49.10. The business has a fifty day moving average price of $30.24 and a 200-day moving average price of $34.82. The firm has a market capitalization of $1.39 billion, a P/E ratio of 35.22 and a beta of 1.00.

Several large investors have recently made changes to their positions in RCUS. Schonfeld Strategic Advisors LLC grew its stake in shares of Arcus Biosciences by 2.0% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 24,900 shares of the company’s stock worth $1,008,000 after purchasing an additional 500 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of Arcus Biosciences by 8.0% in the first quarter. Teacher Retirement System of Texas now owns 7,938 shares of the company’s stock worth $251,000 after purchasing an additional 590 shares during the last quarter. Diversified Trust Co grew its stake in shares of Arcus Biosciences by 7.1% in the fourth quarter. Diversified Trust Co now owns 9,027 shares of the company’s stock worth $365,000 after purchasing an additional 599 shares during the last quarter. Swiss National Bank grew its stake in shares of Arcus Biosciences by 0.7% in the fourth quarter. Swiss National Bank now owns 86,496 shares of the company’s stock worth $3,500,000 after purchasing an additional 600 shares during the last quarter. Finally, Credit Suisse AG grew its stake in shares of Arcus Biosciences by 2.2% in the fourth quarter. Credit Suisse AG now owns 33,784 shares of the company’s stock worth $1,367,000 after purchasing an additional 729 shares during the last quarter. 73.54% of the stock is currently owned by hedge funds and other institutional investors.

In other news, COO Jennifer Jarrett sold 9,617 shares of the firm’s stock in a transaction dated Wednesday, March 16th. The stock was sold at an average price of $31.62, for a total transaction of $304,089.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 19.71% of the company’s stock.

Arcus Biosciences Company Profile (Get Rating)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

Featured Articles

Earnings History and Estimates for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.